Cancer patients with low ARID1A expression would benefit and respond better to the combination of radiotherapy either with DDR inhibitors (DDRi) to increase the load of DNA damage, and/or with immunotherapy to further enhance the functions and the infiltration of immune cells. Here, ARID1A is linked to cancer.